Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Instem upbeat on outlook as it updates on 2016 progress

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.
Instem upbeat on outlook as it updates on 2016 progress
The company's software is used to collate data from clinical trials

Instem Plc (LON:INS), developer and vendor of software used to log clinical trials, said it has started the new year in good heart after providing some granularity on its performance in 2016.

Already-flagged-up contract delays and the “disappointing performance” of Instem Clinical offset the strong performance of the bulk of the business.

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.

In all it won 30 SEND-related contracts for its software – which makes it a leader in this field.

For the 12 months to December 31, revenues increased 11% to £18.1mln, Instem said, giving EBITDA of £1.2mln. Cash at the year-end was £4.4mln.

"Although the slowdown in the early phase clinical market and contract delays were disappointing, other parts of the business continued to perform well and we made significant progress during the year,” said chief executive Phil Reason. 

“Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism."

View full INS profile View Profile

Instem Plc Timeline

Big Picture
September 19 2016

Related Articles

risk-management.jpg
September 18 2017
The top line was driven primarily by the strong growth of the company's Risk Management and Trading Software Division
web domains - browser address bar
July 26 2017
Minds + Machines launched the review in late May after receiving a number of informal bid approaches, and discussions are ongoing.
YouTube
August 14 2017
Overheads have been cut dramatically and the group is focusing on higher margin business.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use